Q2 2025 WAVE Life Sciences Ltd Earnings Call Transcript

Jul 30, 2025 / 12:30 PM GMT

Release Date Price: €7 (-0.71%)

Transcript 10-Q8-K

Key Points

Positve

WAVE Life Sciences Ltd (WVE) has made significant progress in RNA editing, particularly with their AATD clinical program and Eli clinical program for obesity.
The company has delivered positive data from their forward 53 clinical trial of N531 for DMD, showing statistically significant improvements.
WVE 006, their RNA editing oligonucleotide for alpha one antitrypsin deficiency, has shown impressive durability and a favorable safety profile.
The company has expanded its second cohort for the WVE 007 obesity program due to favorable safety and robust active reduction.
WAVE Life Sciences Ltd (WVE) has a strong cash position, with $208.5 million in cash and cash equivalents, expected to fund operations into 2027.

Negative

The company's revenue for the second quarter of 2025 decreased to $8.7 million from $19.7 million in the prior year quarter.
Research and development expenses increased to $43.5 million, driven by spending in the inhibie program and RNA editing programs.
General and administrative expenses rose to $18 million, primarily due to share-based compensation and other external expenses.
The net loss for the second quarter of 2025 was $50.5 million, compared to a net loss of $32.9 million in the prior year quarter.
There is uncertainty regarding the potential for future milestones and payments under the GSK collaboration, which are not included in the cash runway.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

WVE.OQ - WAVE Life Sciences Ltd
Q2 2025 WAVE Life Sciences Ltd Earnings Call
Jul 30, 2025 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello, and welcome to Wave Life Science's 2nd quarter 2025 earnings call. We ask that you please hold all questions until the completion of the formal remarks, at which time You will be given instructions for the question and answer session. Also, as a reminder, this conference is being recorded today. I will now pass the call over to Kate Rouch, Vice President of Corporate Affairs and Investor Relations.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and good morning to everyone on the call. Earlier this morning, we issued a press release outlining our 2nd

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.